Comparative study evaluates usability of a generic GLP-1 injector in relation to a reference device, implying potential substitution.
Despite "other design differences", the proposed generic combination product injector demonstrated comparable usability to the RLD pen, without additional risks. Most observed use errors were not device-specific and were resolved quickly, suggesting limited clinical impact in realworld use. These findings support the potential substitutability of the proposed GLP-1 generic combination product for the RLD and contribute to de-risking the final comparative use Human Factors evaluations required for ANDA.
No takes yet. Share an insight, caveat, or question.
Brunet-Manquat et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: